About CollaGenex

In August 2007, CollaGenex received highly positive results from a Phase 2 clinical trial of Col-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. In 2008, CollaGenex intends to initiate Phase 3 trials for Col-118 and Phase 2 trials for becocalcidiol, a patented Vitamin D analogue licensed from QuatRx Pharmaceuticals Company, for the topical treatment of mild to moderate psoriasis.

In June, U.S. Patent and Trademark Office (USPTO) issues Patent No. 7,232,572, covering the use of tetracyclines in a sub-antibiotic amount, including Oracea, specifically for the treatment of papules and pustules associated with rosacea. In May, the USPTO issues as U.S. Patent No. 7,211,267, covering the use of sub-antimicrobial tetracyclines for the treatment of acne and acne rosacea, including Oracea.

In May, CollaGenex and QuatRx Pharmaceuticals Company enter a licensing agreement under which CollaGenex will develop and commercialize becocalcidiol, a patented Vitamin D analogue developed by QuatRx that is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.

In February, CollaGenex reports positive results of Phase IV clinical study evaluating effects of Oracea® (doxycycline, USP) Capsules, 40 mg, in combination with MetroGel® (metronidazole gel), 1%, as treatment for Rosacea.

In May, CollaGenex receives approval of its NDA for Oracea®, becoming the only FDA-approved systemic product for the treatment of rosacea. Having completed building out its U.S. professional dermatology sales force earlier in the year, CollaGenex launches Oracea in July 2006.

In February, CollaGenex files a Marketing Authorization Application (MAA) for Oracea with the United Kingdom's Medicines & Healthcare Products Regulatory Agency (MHRA). In March, the European Patent Office allows patent application 02731267.7, covering the use of sub anti-microbial doxycycline in the treatment of acne and rosacea, including Oracea. In December, CollaGenex enters into a License and Supply Agreement with MediGene AG for marketing rights to Oracea in the European Union, certain contiguous countries and Russia and receives an upfront fee of $5 million upon signing of the agreement as well as an additional $7.5 million in milestone payments upon the achievement of certain annual sales thresholds.

CollaGenex begins to develop Col-118, one of the compounds from the SansRosa technology, for the treatment of erythema (skin redness).

CollaGenex receives a grant from the National Institutes of Health to fund development of the potent anti-inflammatory effects of incyclinide.

CollaGenex enters agreement with Primus Pharmaceuticals to promote Alcortin™ and Novacort™ to dermatologists.

CollaGenex acquires SansRosa, the assignee of various patent applications covering innovative methods for the treatment of redness associated with rosacea and other skin disorders.

CollaGenex completes restructuring program, eliminating its dental sales force, following FDA approval of a generic form of Periostat®. CollaGenex initiates the expansion of its dermatology sales force.

Phase III trials of Oracea® for the treatment of rosacea initiated.

CollaGenex agrees to sell rights to U.K. and European dental assets to Alliance Pharma plc.

Company initiates dermatology sales and marketing activities.

Company licenses the Restoraderm™ topical drug delivery system.